Authorized purpose: Detect standard fetal biometry views and assist fetal biometry measurements during prenatal ultrasound acquisition and interpretation.
Clinical role
Concurrent view-identification and measurement aid during ultrasound acquisition and interpretation; not a stand-alone diagnostic decision maker.
Images and patients
Ultrasound · Fetal biometry views and structures: cephalic/head, abdomen, and femur
Key limitation
Keep in mind: The labeled use is not first trimester, Doppler, or 3D acquisition. The device was validated only on Butterfly iQ3, GE Voluson S8/S10/E6, Clarius HD3, and Philips IU22/HD7 systems in the packet's study. The IFU is for patients age 18 or older, while the validation demographics report maternal age 15-56; the evidence population is therefore not identical to the labeled population.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Detect standard fetal biometry views and assist fetal biometry measurements during prenatal ultrasound acquisition and interpretation.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetal biometry views and structures: cephalic/head, abdomen, and femur Input: DICOM fetal ultrasound images or clips, or live fetal ultrasound video streamed from a scanner through local HDMI-to-USB capture. Live video supports view identification and caliper suggestions but cannot automatically compute measurements because it is not DICOM; DICOM is required for automated biometric computation. Labeled use is patients age 18 or older at 14 to 41 weeks; validation used 2D grayscale data and four listed ultrasound system families.
Who uses it?Intended users: Qualified and appropriately trained healthcare professionals, including radiologists, obstetricians, sonographers, maternal-fetal medicine specialists, OB/GYNs, and fetal surgeons.
What does the software produce?Output: Identified and labeled cephalic, abdominal, and femoral views; suggested caliper placement; HC, BPD, FL, and AC measurements; and examination reports. The device description also describes GA and EFW computation after view detection and DICOM processing.
What is its most important limitation?Key limitation: The labeled use is not first trimester, Doppler, or 3D acquisition. The device was validated only on Butterfly iQ3, GE Voluson S8/S10/E6, Clarius HD3, and Philips IU22/HD7 systems in the packet's study. The IFU is for patients age 18 or older, while the validation demographics report maternal age 15-56; the evidence population is therefore not identical to the labeled population.
Clinical takeaway. Clinical role: Detect standard fetal biometry views and assist fetal biometry measurements during prenatal ultrasound acquisition and interpretation.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: stand-alone assessment against annotations by three ARDMS-certified sonographers. 417 studies from 15 sites were collected; after exclusions, 397 subjects and 23,544 images remained. Endpoints covered four continuous measurement comparisons and view-identification sensitivity/specificity; no literature review was performed for this audit.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Detect standard fetal biometry views and assist fetal biometry measurements during prenatal ultrasound acquisition and interpretation.
DICOM fetal ultrasound images or clips, or live fetal ultrasound video streamed from a scanner through local HDMI-to-USB capture. Live video supports view identification and caliper suggestions but cannot automatically compute measurements because it is not DICOM; DICOM is required for automated biometric computation. Labeled use is patients age 18 or older at 14 to 41 weeks; validation used 2D grayscale data and four listed ultrasound system families.
Identified and labeled cephalic, abdominal, and femoral views; suggested caliper placement; HC, BPD, FL, and AC measurements; and examination reports. The device description also describes GA and EFW computation after view detection and DICOM processing.
Qualified and appropriately trained healthcare professionals, including radiologists, obstetricians, sonographers, maternal-fetal medicine specialists, OB/GYNs, and fetal surgeons.
The labeled use is not first trimester, Doppler, or 3D acquisition. The device was validated only on Butterfly iQ3, GE Voluson S8/S10/E6, Clarius HD3, and Philips IU22/HD7 systems in the packet's study. The IFU is for patients age 18 or older, while the validation demographics report maternal age 15-56; the evidence population is therefore not identical to the labeled population.
FDA packet: stand-alone assessment against annotations by three ARDMS-certified sonographers. 417 studies from 15 sites were collected; after exclusions, 397 subjects and 23,544 images remained. Endpoints covered four continuous measurement comparisons and view-identification sensitivity/specificity; no literature review was performed for this audit.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: stand-alone assessment against annotations by three ARDMS-certified sonographers. 417 studies from 15 sites were collected; after exclusions, 397 subjects and 23,544 images remained. Endpoints covered four continuous measurement comparisons and view-identification sensitivity/specificity; no literature review was performed for this audit.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
DEEPECHO regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K242594
Samplen=397
Sites15
IndependenceIndependence not established
K242594
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K242594. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM fetal ultrasound images or clips, or live fetal ultrasound video streamed from a scanner through local HDMI-to-USB capture. Live video supports view identification and caliper suggestions but cannot automatically compute measurements because it is not DICOM; DICOM is required for automated biometric computation. Labeled use is patients age 18 or older at 14 to 41 weeks; validation used 2D grayscale data and four listed ultrasound system families.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Cloud-based standalone SaMD accessible from laptops, tablets, or desktops without a local server; DICOM upload links or creates patient/exam records from metadata, while live scanner video uses HDMI-to-USB capture into the local device. The packet does not establish a specific PACS/RIS/EHR interface.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes DEEPECHO as cloud-based standalone software accessed from laptops, tablets, or desktops without local server installation; for real-time use, scanner images reach the local device running DEEPECHO via HDMI-to-USB video capture. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "DEEPECHO is a cloud-based standalone software that can be accessed from various devices, such as laptops, tablets, or desktops, without the need for local server installation." … "images are acquired using an HDMI cable that is plugged into the local device (e.g., computer, tablet) running DEEPECHO, through an HDMI to USB Video Capture.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Identified and labeled cephalic, abdominal, and femoral views; suggested caliper placement; HC, BPD, FL, and AC measurements; and examination reports. The device description also describes GA and EFW computation after view detection and DICOM processing.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Identified and labeled cephalic, abdominal, and femoral views; suggested caliper placement; HC, BPD, FL, and AC measurements; and examination reports. The device description also describes GA and EFW computation after view detection and DICOM processing.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes DEEPECHO as cloud-based standalone software accessed from laptops, tablets, or desktops without local server installation; for real-time use, scanner images reach the local device running DEEPECHO via HDMI-to-USB video capture. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DEEPECHO is a cloud-based standalone software that can be accessed from various devices, such as laptops, tablets, or desktops, without the need for local server installation." … "images are acquired using an HDMI cable that is plugged into the local device (e.g., computer, tablet) running DEEPECHO, through an HDMI to USB Video Capture.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Cloud-based standalone SaMD accessible from laptops, tablets, or desktops without a local server; DICOM upload links or creates patient/exam records from metadata, while live scanner video uses HDMI-to-USB capture into the local device. The packet does not establish a specific PACS/RIS/EHR interface.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
1Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K242594 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.
Authorized purpose: Koios Decision Support (DS) is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/MLderived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS software may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management.
Non-invasive processing of ultrasound images to detect, measure, and calculate relevant medical parameters of structures and function in patients with suspected disease, with Quality Score feedback.
Modality
Ultrasound
Anatomy
Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
Authorized purpose: PIUR tUS Infinity supports a computer-aided thyroid ultrasound workflow that identifies thyroid lobes and margins, calculates volume, marks and quantifies nodules, and provides user-selected ACR TI-RADS parameters subject to user review and confirmation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.